I had a conversation with a representative of the company. Below is a summary

• For the new quartz plant, the average utilization rate in the previous year was about 40-50% and for granite it was 70-80%. Quartz utilization will improve going forward as sales pickup
• For the recent quarter, the quartz plant was shut down for ~20 days. Without this, their production and utilization would have been higher. (Possibly sales also would have been higher but this is my assumption)
• No immediate plans to add capacity and therefore they dont expect any additional funding for another 2 years. This is the status as of now but may change.
• Cash generated would go to service the debt and bring it down. That is the near term plan.
• Vizag plant has provision for adding lines so any expansion will use lesser capital as it will be a brownfield expansion
• Quartz uses a polymer and is not a straight extraction like granite. Polymer is driven by Crude prices. This is a positive as Crude price falls. (Not a big positive in my view as I read somewhere that polymer is a small component. Will need to check)
• Branding is through Quantra and it is doing well. Pokarna will have step up efforts to improve this.
• Primary competition is other companies having access to Breton technology (5-6 companies). Market is very large in US and Canada to accomodate all.
• Chinese quartz is of inferior quality and is not direct competition to them (not sure if this is correct. need someone from US to confirm this)
• Recent data on housing starts a positive. Company expects demand to grow (very generic on this so not much insight)

All in all, most of the data was a reconfirmation of what we know with 1-2 additional insights. Will have to watch the sales growth and debt reduction closely.

Disc - Invested. Please do your own due diligence

Will double sourcing, suppliers from India by 2020: Ikea

Read more at: http://www.moneycontrol.com/news/business/will-double-sourcing-suppliersindia-by-2020_2732381.html?utm_source=ref_article

On celebrex patent search, i got this on wiki

It is legally available in many jurisdictions as a generic under several brand names.
In the US, celecoxib was covered by three patents, two of which expired May 30, 2014, and one of which (US RE44048) was due to expire December 2, 2015.

On March 13, 2014, that patent was found to be invalid for double patenting.
Upon the patent expiry on May 30, 2014, FDA approved the first versions of celecoxib generic.

As per there recent concall, management was talking about launch of celebrex in December this year, [he was like we will be there on day 1 though he was not sure of date]
So he might be talking about this patent expiration.

US RE44048 patent
Issued: March 5, 2013
Assignee(s): G.D. Searle LLC
Patent expiration dates:
o June 2, 2015
TREATMENT OF PRIMARY DYSMENORRHEA, JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN, ANKYLOSING SPONDYLITIS, RHEUMATOID ARTHRITIS
o December 2, 2015
Pediatric exclusivity
I think alembic will be targeting pediatric population.
I may be wrong at arriving this conclusion, seniors n fellow VPs ur views needed

Disc-invested from lower levels.

Already mentioned that call highlights by Capital Mkt.